Psyence Biomedical Ltd. Statistics
Share Statistics
Psyence Biomedical Ltd. has 3.43M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 3.43M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 189 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 137.68K, so 16.29% of the outstanding shares have been sold short.
| Short Interest | 137.68K |
| Short % of Shares Out | 16.29% |
| Short % of Float | 21.29% |
| Short Ratio (days to cover) | 0.07 |
Valuation Ratios
The PE ratio is -10.89 and the forward PE ratio is null.
| PE Ratio | -10.89 |
| Forward PE | null |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | -50.78 |
| P/FCF Ratio | -188.82 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Psyence Biomedical Ltd..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.09, with a Debt / Equity ratio of -0.95.
| Current Ratio | 0.09 |
| Quick Ratio | 0.09 |
| Debt / Equity | -0.95 |
| Total Debt / Capitalization | -1.99K |
| Cash Flow / Debt | -0.28 |
| Interest Coverage | -51.98 |
Financial Efficiency
Return on equity (ROE) is 4.66% and return on capital (ROIC) is 524.51%.
| Return on Equity (ROE) | 4.66% |
| Return on Assets (ROA) | -45.19% |
| Return on Capital (ROIC) | 524.51% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -5.12M |
| Employee Count | 10 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is -0.42, so Psyence Biomedical Ltd.'s price volatility has been lower than the market average.
| Beta | -0.42 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 3.63 |
| 200-Day Moving Average | 31.76 |
| Relative Strength Index (RSI) | 36.45 |
| Average Volume (20 Days) | 2.43M |
Income Statement
| Revenue | n/a |
| Gross Profit | -240 |
| Operating Income | -2.75M |
| Net Income | -51.16M |
| EBITDA | -2.75M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -7.85 |
Balance Sheet
The company has 762.80K in cash and 10.45M in debt, giving a net cash position of -9.69M.
| Cash & Cash Equivalents | 762.80K |
| Total Debt | 10.45M |
| Net Cash | -9.69M |
| Retained Earnings | -57.46M |
| Total Assets | 1.13K |
| Working Capital | -10.98K |
Cash Flow
In the last 12 months, operating cash flow was -2.95M and capital expenditures -5.73K, giving a free cash flow of -2.95M.
| Operating Cash Flow | -2.95M |
| Capital Expenditures | -5.73K |
| Free Cash Flow | -2.95M |
| FCF Per Share | -0.45 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
PBM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -402.56% |
| FCF Yield | -44.18% |
Analyst Forecast
Currently there are no analyst rating for PBM.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Nov 26, 2024. It was a backward split with a ratio of 1:75.
| Last Split Date | Nov 26, 2024 |
| Split Type | backward |
| Split Ratio | 1:75 |
Scores
| Altman Z-Score | -7188.72 |
| Piotroski F-Score | 2 |